Sentences with phrase «found ovarian cancer cells»

The researchers then used a combination of existing United States Food and Drug Administration - approved drugs to target autophagy and found ovarian cancer cells to be highly sensitive to these drugs in several different mouse cancer models — even among cells resistant to standard chemotherapy.

Not exact matches

Researchers led by Patricia Donahoe and Xiaolong Wei of Massachusetts General Hospital and Harvard Medical School found that the common chemotherapy agent doxorubicin actually encourages the growth of ovarian cancer stem cells.

Chemotherapy drugs designed to kill tumors may actually encourage ovarian cancer by stimulating the growth of cells that give rise to the malignancy, a new study finds.

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells» resistance to paclitaxel.

In order to find out how and why ovarian cancer cells grow and take on such lethal characteristics, Dr. Shepherd and his team grow the cancer cells in 3D structures, called «spheroids» — the same way the cancer cells grow in patients.

Analyzing white blood cells from 934 patients and 1,698 healthy controls, they found BRCA1 methylation among 6.4 % of patients diagnosed with ovarian cancer, contrasting 4.2 % among controls.

«For example, we found that highly aggressive ovarian cancer cells are glutamine - dependent, and in our laboratory studies, we showed that depriving such cells of external sources of glutamine — as some experimental drugs do — was an effective way to kill late - stage cells.

Their findings in the study «Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells,» which has been published in The Journal of Cell Biology, suggest that this FDA - approved ovarian cancer medicine has the potential to treat a wider range of cancer types than currently indicated.

In particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancers.

The research team with international collaborators analysed more than 100 patient samples from ovarian and other cancer types to discover a distinct population of cells found in some tumours.

The scientists found that, at certain concentrations, one of the compounds of the series selectively killed human ovarian cancer cells without harming healthy cells.

For the new study, described in the October 23rd issue of Nature Communications, scientists at the Johns Hopkins Kimmel Cancer Center and Dana Farber Cancer Institute in Boston collected tissue samples containing normal cells, ovarian cancers, metastases that had spread elsewhere, and small cancers found in the fallopian tubes, which included single cell layers of cancer called «p53 signatures» and serous tubal intraepithelial carcinoma, or STIC leCancer Center and Dana Farber Cancer Institute in Boston collected tissue samples containing normal cells, ovarian cancers, metastases that had spread elsewhere, and small cancers found in the fallopian tubes, which included single cell layers of cancer called «p53 signatures» and serous tubal intraepithelial carcinoma, or STIC leCancer Institute in Boston collected tissue samples containing normal cells, ovarian cancers, metastases that had spread elsewhere, and small cancers found in the fallopian tubes, which included single cell layers of cancer called «p53 signatures» and serous tubal intraepithelial carcinoma, or STIC lecancer called «p53 signatures» and serous tubal intraepithelial carcinoma, or STIC lesions.

In earlier research, Barbolina discovered that a fractalkine receptor — a protein found on the cell surface — is expressed in the majority of ovarian cancer cases.

Blocking a protein found on the surface of ovarian cancer cells could prevent or reduce the spread of the disease to other organs, according to new research at the University of Illinois at Chicago.

When the researchers tested the circuit in vitro, they found that it was able to detect ovarian cancer cells from amongst other noncancerous ovarian cells and other cell types.

They found that tumor cells with the mutant genes were particularly sensitive to a drug, olaparib, recently approved for the treatment of hereditary ovarian cancer.

Those findings are among results of six studies of investigational chimeric antigen receptor (CAR) T cells for both adult and pediatric leukemias, adult lymphomas, and ovarian cancer which will be presented during the 2016 American Society of Clinical Oncology Annual Meeting.

The team found evidence of the process in several other cell types, including breast, ovarian, umbilical cord, and kidney cancer cells.

In a May 2014 study, Nagrath and colleagues found that highly aggressive ovarian cancer cells were glutamine - dependent and that depriving the cells of external sources of glutamine — as some experimental drugs do — was an effective way to kill late - stage ovarian cancer cells in the lab.

Liron Bar - Peled and Lynne Chantranupong, who are both authors of the Science article and graduate students in Sabatini's lab, found that GATOR1 itself is mutated in several cancers, including glioblastomas and ovarian cancers, and that cancer cells with these mutations are also highly sensitive to treatment with rapamycin.

In this video Dr. Odunsi discusses a new study that found that higher T - cell diversity in ovarian cancer is associated with poor overall survival.

The FDA - approved antihelminthic drug, pyrvinium pamoate (PPAM), was found in a screening for compounds that promoted β - catenin turnover and, thereby, inhibiting Wnt signaling in ovarian and other cancer cells (Table 1)[51, 56].

The good news is that if markers for these tubal cells can be found, then blood tests, advanced Pap smears, or direct tests on tubal tissue might spot ovarian cancer earlier, the study authors said.